Updated: Apr 20, 2009
Millipedes are elongated cylindrical creatures that bear 2 pairs of legs per body segment and are found in a wide variety of habitats. They are generally very slow-moving creatures and are relatively innocuous. Falling into the class Diplopoda and the phylum Arthropoda, millipedes comprise some 7000 species.
Millipedes do not have biting mouthparts or fangs. Their medical importance comes from their ability to secrete an irritating defensive liquid from pores along their sides. Such secretions contain benzoquinones, aldehydes, hydrocyanic acid, phenols, terpenoids, nitroethylbenzenes, and other substances.
Some species are capable of squirting these liquids to distances of up to 25 cm.
No deaths have been documented from millipede exposures, and it is unlikely that such an exposure could be fatal, even to a small child.
The history may indicate that a patient was handling a millipede. On occasion, the history of a patient (eg, a sleeping victim, small child) may be obscure.
Centipede Envenomations
Significant conjunctivitis or dermatitis caused by toxic millipede secretions can be treated with topical steroids.
These agents prevent further ulcerations of the cornea and should be given in consultation with an ophthalmologist.
Decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Solution: 1-2 gtt into conjunctival sac qh during day and q2h during night; once desired response is obtained, use 1 gtt q4h; may reduce to 1 gtt tid/qid to control symptoms
Suspension: Shake well before using, instill 1-2 gtt into conjunctival sac 2-4 times qd; may increase dosing frequency during initial 1-2 d prn
Administer as in adults
None reported
Documented hypersensitivity; viral, fungal, or tubercular skin lesions
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Caution in hypertension; known to cause cataract formation with chronic use; in prolonged use, withdraw treatment by gradually decreasing frequency of applications to avoid adrenal insufficiency
Treats steroid-responsive inflammatory ocular conditions that have a risk of infection.
Solution: Instill 1-3 gtt q2-3h while awake and hs until favorable response
Ointment: Apply 0.5-inch ribbon into lower conjunctival sac 1-4 times qd and once hs
<2 months: Not established
>2 months: Administer as in adults
Decreases effects of silver compounds and gentamicin
Documented hypersensitivity; mycobacterial infection
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Caution in severe dried eyes; ointment may retard corneal epithelial healing
Used to treat erythema and skin irritation that result from chemical insults. Prevent further ulcerations of the skin.
Treats inflammatory dermatitis that is responsive to steroids. Decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.
Apply thin film bid/tid until favorable response
Administer as in adults
None reported
Documented hypersensitivity; fungal, viral, and bacterial skin infections
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Do not use in patients diagnosed with decreased skin circulation
Treats inflammatory dermatitis responsive to steroids. Decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.
Apply thin film to affected area tid/qid until favorable response
Administer as in adults
None reported
Documented hypersensitivity; viral, fungal, or tubercular skin infections
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Prolonged use, applying over large surface areas, application of potent steroids, and occlusive dressings may increase systemic absorption of corticosteroids and may cause Cushing syndrome, reversible HPA axis suppression, hyperglycemia, and glycosuria
Dar NR, Raza N, Rehman SB. Millipede burn at an unusual site mimicking child abuse in an 8-year-old girl. Clin Pediatr (Phila). Jun 2008;47(5):490-2. [Medline].
Hare T. Poisonous Dwellers of the Desert. Tucson, AZ: Southwest Parks and Monuments Association; 1995.
Hendrickson RG. Millipede exposure. Clin Toxicol (Phila). 2005;43(3):211-2. [Medline].
Hudson BJ, Parsons GA. Giant millipede 'burns' and the eye. Trans R Soc Trop Med Hyg. Mar-Apr 1997;91(2):183-5. [Medline].
Mason GH, Thomson HD, Fergin P, Anderson R. Spot diagnosis. The burning millipede. Med J Aust. Jun 6 1994;160(11):718, 726. [Medline].
Peters S. A Colour Atlas of Arthropods in Clinical Medicine. Barcelona, Spain: Wolfe Publishing Ltd; 1992.
Radford AJ. Giant millipede burns in Papua New Guinea. P N G Med J. Sep 1976;18(3):138-41. [Medline].
Radford AJ. Millipede burns in man. Trop Geogr Med. Sep 1975;27(3):279-87. [Medline].
Williams LA, Singh PD, Caleb-Williams LS. Biology and biological action of the defensive secretion from a Jamaican millipede. Naturwissenschaften. 1997;84(4):143-4. [Medline].
millipede envenomations, millipede sting, millipede bite, Diplopoda, Arthropoda, millipede exposure, centipede
Robert L Norris, MD, Associate Professor, Department of Surgery; Chief, Division of Emergency Medicine, Stanford University Medical Center
Robert L Norris, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, California Medical Association, International Society of Toxinology, Society for Academic Emergency Medicine, and Wilderness Medical Society
Disclosure: Nothing to disclose.
James Li, MD, Former Assistant Professor, Division of Emergency Medicine, Harvard Medical School; Board of Directors, Remote Medicine
Disclosure: Nothing to disclose.
John T VanDeVoort, PharmD, Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals
John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists
Disclosure: Nothing to disclose.
Richard H Sinert, DO, Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center
Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Scott H Plantz, MD, FAAEM, Associate Clinical Professor of Emergency Medicine, Rosalind Franklin University of Medicine and Science, Chicago Medical School; Medical Director, WeCare Med, Inc
Scott H Plantz, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine
Disclosure: Nothing to disclose.
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)